
Nkarta, Inc. (NKTX) Stock Forecast & Price Target
Nkarta, Inc. (NKTX) Analyst Ratings
Bulls say
Nkarta Inc. is experiencing positive momentum in patient enrollment due to the decision to reincorporate standardized lymphodepletion with fludarabine, which is expected to enhance the efficacy of its therapies. The company is positioned as an attractive investment in the emerging field of allogeneic, engineered NK cell therapies, offering a more affordable valuation compared to its peers. Additionally, Nkarta's focus on harnessing the self-regulated cytotoxicity of NK cells aims to address significant limitations associated with existing CAR-T therapies, highlighting its potential for growth in the cancer treatment market.
Bears say
Nkarta Inc. is experiencing a notable decline in funding for research and development (R&D) and selling, general, and administrative (SG&A) expenses, with R&D spending down 14% sequentially and SG&A spending reduced by 48%, leading to concerns about its financial sustainability. Additionally, the upcoming protocol amendment for NKX019, which reintroduces fludarabine into the lymphodepletion regimen, is expected to limit the robustness of data interpretations due to a constrained patient population. Management's decision to delay preliminary data disclosures until FY26 to present a comprehensive dataset further emphasizes the uncertainties surrounding the company’s clinical progress and financial outlook.
This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction
Start investing in Nkarta, Inc. (NKTX)
Order type
Buy in
Order amount
Est. shares
0 shares